
16
RELX
Annual Report 2024 | Market segments
Business overview
Scientific, Technical & Medical helps researchers and healthcare
professionals advance science and improve health outcomes by
combining high-quality scientific and medical information and
trusted data sets with leading technology to deliver analytical
tools that facilitate insights and critical decision-making.
Elsevier is headquartered in Amsterdam, with principal sites in
Boston, New York, Philadelphia and St. Louis in North America;
London, Oxford, Frankfurt, Munich, Madrid and Paris in Europe;
Beijing, Shanghai, Chennai, Delhi, Chatswood, Singapore and
Tokyo in Asia Pacific, and Rio de Janeiro in South America.
It has 9,700 employees with customers in over 170 countries
and territories.
Revenues for the year ended 31 December 2024 were £3,051m,
compared with £3,062m in 2023 and £2,909m in 2022. In 2024,
46% of revenue came from North America, 22% from Europe
and the remaining 32% from the rest of the world. Subscription
revenue represented 74% of total revenue and transactional
revenues represented 26%.
Elsevier’s customers are scientists, research leaders, librarians,
medical researchers, doctors, nurses, allied health professionals
and students, as well as hospitals, academic and research
institutions, health insurers, managed healthcare organisations,
research-intensive corporations, funders, and governments.
Elsevier’s services across Academic & Government, Corporate
and Health markets focus on: Databases, Tools and Electronic
reference; Primary Research; and Print products. In each of these
markets, our objective is to be a trusted partner to the customers
we serve and to be known for quality. Databases, Tools and
Electronic Reference, together with Corporate Primary Research,
accounts for around 45% of STM revenues, with Academic &
Government Primary Research accounting for a similar amount,
all in electronic format. Under 10% of revenues are derived from
Print sales.
Databases & Tools & Electronic Reference.
Elsevier’s databases,
tools and electronic reference products help customers and users
solve complex problems and make critical decisions, and we are
enhancing these capabilities with generative AI across all our
business areas. Solutions include Engineering Village, Interfolio,
Pure, SciVal, and Scopus in Academic & Government; Embase,
Reaxys, and SciBite in Corporate; and ClinicalKey, ClinicalPath,
Complete Anatomy, HESI, Osmosis, Shadow Health, and Sherpath
for Health.
Elsevier’s research intelligence portfolio of products combines
quality, curated content and extensive data sets with responsible
AI and large language model (LLM) technology to help
researchers, academic leaders, policy-makers, funders and
R&D-led corporations to generate insights, set and implement
research strategies and make decisions with confidence. This
portfolio integrates with and enhances the systems institutions
rely on, with interoperability driven by Application Programming
Interface technologies (APIs). In early 2024, Elsevier launched
Scopus AI, a generative AI-enhanced research tool integrated
into the Scopus platform to help academics and researchers
get deeper research insights faster, navigate and understand
different disciplines more easily and support interdisciplinary
collaboration.
For Corporate R&D, SciBite tools and the data as a service offering
follow Elsevier’s ontology-led approach and support corporate
R&D customers in extracting scientific insights from vast
amounts of unstructured text and databases. In 2024 Elsevier
launched SciBite Chat, a new AI-powered tool built atop SciBite
We deliver insights that help universities,
research institutions, governments and
funders achieve their strategic goals. We help
researchers discover and share knowledge,
collaborate, and accelerate innovation. We help
librarians provide trusted, high-quality
information to their universities. We help
innovators transform the latest knowledge into
new products. We help health professionals
improve patient care, and educators train the
next generation of doctors and nurses.
§
We help ensure quality research accelerates
progress for society by helping validate,
improve and disseminate over 17% of the
world’s scientific articles
§
Elsevier’s over 3,000 journals published
more than 720,000 articles in 2024, from
over 3.5m submitted
§
243 of 244 science and economics Nobel Prize
winners since 2000 have published in an
Elsevier journal
§
ScienceDirect, the world’s largest platform
dedicated to peer-reviewed primary scientific
and medical research, hosts over 22m pieces
of content from over 5,100 journals and over
48,000 e-books, and has over 20m monthly
researchers. Its Ahrefs ranking places it as
one of the Top 200 platforms on the internet
§
SciVal is a web-based analytics solution that
provides insights into the research
performance of over 24,500 academic,
industry and government research institutions
§
Scopus is an expertly curated abstract and
citation database with content from over 30,000
journals from more than 7,000 publishers to
help researchers track and discover global
knowledge in all fields
§
ClinicalKey, the flagship clinical reference
platform, is used by doctors, nurses,
medical students and educators at over 5,500
institutions in over 80 countries and territories
§
Sherpath, an adaptive teaching and learning
solution for nursing students, provides
personalised learning paths at over 700
institutions, supporting more than 300,000
course enrolments
§
Reaxys, Elsevier’s chemistry research
platform, utilises data on 298m substances,
68m reactions, with over 118m documents
and 44m patents
§
Pure is one of the world's leading commercially
available Research Information Management
Systems integrating a wide range of research
databases and research outputs, with more
than 1.1m researcher profiles and used by
more than 500 of the world’s institutions
Scientific, Technical & Medical